Upjohn Company Profile

What is the competitive landscape for UPJOHN

UPJOHN has thirteen approved drugs.

There are three US patents protecting UPJOHN drugs.

There are thirty-three patent family members on UPJOHN drugs in thirty-three countries and forty supplementary protection certificates in thirteen countries.

Summary for Upjohn

International Patents:	33
US Patents:	3
Tradenames:	12
Ingredients:	9
NDAs:	13

Drugs and US Patents for Upjohn

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Upjohn	CELEBREX	celecoxib	CAPSULE;ORAL	020998-003	Aug 29, 2002	AB	RX	Yes	Yes
Upjohn	DETROL	tolterodine tartrate	TABLET;ORAL	020771-001	Mar 25, 1998	AB	RX	Yes	No
Upjohn	LYRICA	pregabalin	SOLUTION;ORAL	022488-001	Jan 4, 2010	AA	RX	Yes	Yes
Upjohn	RELPAX	eletriptan hydrobromide	TABLET;ORAL	021016-002	Dec 26, 2002	AB	RX	Yes	Yes
Upjohn	XANAX	alprazolam	TABLET;ORAL	018276-001	Approved Prior to Jan 1, 1982	AB	RX	Yes	No
Upjohn	XANAX	alprazolam	TABLET;ORAL	018276-003	Approved Prior to Jan 1, 1982	AB	RX	Yes	Yes
Upjohn	XANAX XR	alprazolam	TABLET, EXTENDED RELEASE;ORAL	021434-001	Jan 17, 2003	AB	RX	Yes	No

Expired US Patents for Upjohn

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Upjohn	CELEBREX	celecoxib	CAPSULE;ORAL	020998-003	Aug 29, 2002	5,972,986*PED
Upjohn	DETROL LA	tolterodine tartrate	CAPSULE, EXTENDED RELEASE;ORAL	021228-001	Dec 22, 2000	6,630,162*PED
Upjohn	EFFEXOR XR	venlafaxine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	020699-001	Oct 20, 1997	4,535,186*PED
Upjohn	INSPRA	eplerenone	TABLET;ORAL	021437-003	Sep 27, 2002	4,559,332*PED
Upjohn	LYRICA	pregabalin	CAPSULE;ORAL	021446-008	Dec 30, 2004	5,563,175
Upjohn	XALATAN	latanoprost	SOLUTION/DROPS;OPHTHALMIC	020597-001	Jun 5, 1996	5,422,368
Upjohn	XANAX	alprazolam	TABLET;ORAL	018276-001	Approved Prior to Jan 1, 1982	3,987,052

Paragraph IV (Patent) Challenges for UPJOHN drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Capsules	25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg		2008-12-30
	Extended-release Tablets	330 mg		2018-01-29
	Extended-release Tablets	330 mg		2018-01-29
	Tablets	25 mg and 50 mg		2006-09-27
	Extended-release Capsules	2 mg and 4 mg		2007-07-30
	Capsules	50 mg		2008-03-21
	Oral Solution	20 mg/mL		2010-05-19
	Extended-release Tablets	82.5 mg and 165 mg		2018-02-02
	Extended-release Tablets	82.5 mg and 165 mg		2018-02-02
	Tablets	20 mg and 40 mg		2010-03-29
	Extended-release Tablets	37.5 mg, 75 mg and 150 mg		2007-05-03

International Patents for Upjohn Drugs

Country	Patent Number	Estimated Expiration
Costa Rica	9950
Eurasian Patent Organization	200800931
Netherlands	2000281
Norway	20081816
Peru	20070693
South Africa	200803115
Spain	2449231

Supplementary Protection Certificates for Upjohn Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0731795	10075033	Germany		PRODUCT NAME: CELECOXIB; NAT. REGISTRATION NO/DATE: 48802.00.00 20000518; FIRST REGISTRATION: SE 14838 19991203
0720599	122014000088	Germany		PRODUCT NAME: EZETIMIB ODER PHARMAZEUTISCH ANNEHMBARE SALZE DAVON IN KOMBINATION MIT ATORVASTATIN ODER PHARMAZEUTISCH ANNEHMBARE SALZE DAVON, INSBESONDERE ATORVASTATIN ALS ATORVASTATINCALCIUMTRIHYDRAT; NAT. REGISTRATION NO/DATE: 90223.00.00 20141113; FIRST REGISTRATION: FRANKREICH CIS: 6 928 917 6 20140912
3461484	2021C/515	Belgium		PRODUCT NAME: ROCLANDA - LATANOPROST / NETARSUDIL; AUTHORISATION NUMBER AND DATE: EU/1/20/1502 20210108
1003503	30/2006	Austria		PRODUCT NAME: AMLODIPIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SAEUREADDITIONSALZ DESSELBEN IN KOMBINATION MIT ATORVASTATIN ODER EINEM PHARMAZEUTISCH ANNEHMBAREN SALZ DESSELBEN; NAT. REGISTRATION NO/DATE: 1-26271, 1-26273 20060330; FIRST REGISTRATION: FR 369300.9;369301.5; 369302.1;369303.8;369304.4;369305.0; 20050707
0364417	61/1997	Austria		PRODUCT NAME: LATANOPROST UND SEINE THERAPEUTISCH AKTIVEN UND PHYSIOLOGISCH ANNEHMBAREN DERIVATE; NAT. REGISTRATION NO/DATE: 1-22019 19970627; FIRST REGISTRATION: SE 12716 19960718
0247633	62/1997	Austria		PRODUCT NAME: ATORVASTATIN CALCIUM; NAT. REGISTRATION NO/DATE: 1-21926, 1-21927, 1-21928 19970411; FIRST REGISTRATION: GB PL 00018/0240 - PL 00018/0242 19961107
0364417	SPC/GB97/014	United Kingdom		PRODUCT NAME: LATANOPROST (I.E. 13,14-DIHYDRO-17-PHENYL-18,19,20-TRINOR-PGF-ALPHA-ISOPROPYLESTER); NAT. REGISTRATION NO/DATE: 00032/0220 19961216; FIRST REGISTRATION: SE 12716 19960718; SPC EXTENSION AUTHORISATION: PL00057/1057-008 20101216

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Upjohn

Pharmaceutical Competitive Landscape Analysis: Upjohn – Market Position, Strengths & Strategic Insights

In the ever-evolving pharmaceutical industry, understanding the competitive landscape is crucial for success. This article delves into the market position, strengths, and strategic insights of Upjohn, a key player in the pharmaceutical sector. We'll explore how Upjohn has navigated the complex world of drug development, manufacturing, and distribution, and examine its role in the broader context of the global pharmaceutical market.

The Evolution of Upjohn

From Humble Beginnings to Industry Giant

The Upjohn Company, founded in 1886 by Dr. William E. Upjohn in Hastings, Michigan, has a rich history of pharmaceutical innovation[1]. What began as a small operation focused on producing easily digestible pills soon grew into a major force in the industry. Upjohn's journey from a local business to a global pharmaceutical powerhouse is a testament to its commitment to scientific advancement and patient care.

Breakthrough Innovations

One of Upjohn's most significant contributions to the pharmaceutical world was its development of a process for large-scale cortisone production in 1952[1]. This breakthrough, achieved by biochemists Dury Peterson and Herb Murray, revolutionized the treatment of various inflammatory conditions. The company's innovative spirit didn't stop there. Upjohn, in collaboration with Schering, went on to develop prednisone, a more potent steroid, through bacterial fermentation[1].

Upjohn's Market Position

A Portfolio of Iconic Brands

Upjohn's market position has been bolstered by its portfolio of well-known pharmaceutical products. Before its acquisition by Pfizer, Upjohn was renowned for drugs such as:

• Xanax (anxiety treatment)
• Halcion (insomnia medication)
• Motrin (pain reliever)
• Lincocin (antibiotic)
• Rogaine (hair loss treatment)[1]

These products not only generated significant revenue but also established Upjohn as a trusted name in pharmaceuticals.

Global Reach and Market Penetration

As part of Pfizer, Upjohn expanded its global footprint, serving more than 100 markets worldwide[3]. This extensive reach allowed the company to tap into diverse markets, including emerging economies with growing healthcare needs.

"We are creating a new champion for global health—one poised to bring world-class medicines to patients across a wide range of therapeutic areas." - Dr. Albert Bourla, Pfizer CEO[2]

Strengths and Competitive Advantages

Research and Development Prowess

Upjohn's strength in R&D has been a cornerstone of its success. The company's development of the Upjohn dihydroxylation in 1976 is a prime example of its contributions to chemical research[1]. This commitment to scientific innovation has allowed Upjohn to stay at the forefront of drug discovery and development.

Manufacturing Excellence

With a network of nine dedicated manufacturing sites, Upjohn has established a reputation for quality and reliability in drug production[3]. This manufacturing capability ensures a steady supply of medicines to markets around the world, a critical factor in maintaining market share and customer trust.

Diverse Product Portfolio

Upjohn's portfolio spans multiple therapeutic areas, including:

• Cardiovascular
• Pain management
• Psychiatry
• Urology[3]

This diversification helps mitigate risks associated with market fluctuations in any single therapeutic area.

Strategic Insights

Leveraging Established Brands

Upjohn's strategy has involved capitalizing on its portfolio of established medicines. By focusing on well-known brands with proven track records, the company has been able to maintain a strong market presence even as patents expire.

Emerging Market Focus

A key aspect of Upjohn's strategy has been its emphasis on emerging markets. The company has positioned itself to take advantage of growing healthcare needs in developing countries, where established medicines can play a crucial role in improving public health.

Adaptation to Changing Market Dynamics

The pharmaceutical industry is constantly evolving, with new challenges arising from regulatory changes, patent expirations, and emerging competitors. Upjohn has demonstrated adaptability in the face of these changes, as evidenced by its merger with Mylan to form Viatris in 2020[2].

The Mylan Merger: A New Chapter

Creating a Global Pharmaceutical Powerhouse

The merger of Upjohn with Mylan in 2020 marked a significant shift in the company's trajectory. This strategic move created Viatris, a new entity with enhanced capabilities and a broader global reach[6].

Synergies and Expanded Capabilities

The combination of Upjohn's established brands and Mylan's diverse portfolio of generic and complex medicines has created a company with:

• Increased scale
• Expanded geographic presence
• Diversified product offerings
• Enhanced R&D capabilities[7]

Financial Implications

The merger was expected to create a company with significant financial strength. While specific figures were not provided in the search results, the combined entity was positioned to leverage the financial resources of both Upjohn and Mylan to drive growth and innovation.

Challenges and Future Outlook

Patent Expirations and Generic Competition

Like many pharmaceutical companies, Upjohn has faced challenges related to patent expirations on key products. The company's strategy of focusing on established medicines helps mitigate this risk, but continued innovation will be crucial for long-term success.

Regulatory Environment

The pharmaceutical industry operates in a highly regulated environment. Upjohn's future success will depend on its ability to navigate complex regulatory landscapes across different markets.

Healthcare Reform

Potential changes in healthcare policies, particularly in the United States, could impact Upjohn's business model. The company will need to remain agile and responsive to policy shifts that affect drug pricing and market access[8].

Competitive Analysis

Market Share and Positioning

While specific market share data for Upjohn was not provided in the search results, its merger with Mylan to form Viatris created a company with a significant presence in the global pharmaceutical market. The combined entity's diverse portfolio and global reach position it as a major competitor in the industry.

Key Competitors

Upjohn, now part of Viatris, competes with other major pharmaceutical companies in various therapeutic areas. While specific competitor information was not detailed in the search results, it's likely that the company faces competition from both large pharmaceutical corporations and generic drug manufacturers.

Differentiation Strategy

Upjohn's differentiation strategy appears to focus on:

1. Leveraging established brand recognition
2. Expanding in emerging markets
3. Maintaining a diverse product portfolio
4. Emphasizing manufacturing quality and reliability

Innovation and Future Growth

Research and Development Focus

While Upjohn's historical strength has been in established medicines, continued investment in R&D will be crucial for future growth. The company's experience in areas such as steroid development and chemical research provides a foundation for ongoing innovation.

Potential Growth Areas

Based on industry trends, potential areas for future growth could include:

• Biosimilars
• Complex generics
• Treatments for chronic diseases in emerging markets
• Digital health solutions

The Role of Upjohn in Global Health

Access to Medicines

Upjohn's focus on established medicines plays a crucial role in global health by providing access to proven treatments in markets where newer, more expensive drugs may be less accessible.

Public Health Impact

The company's portfolio of cardiovascular, pain management, and psychiatric medications addresses some of the most prevalent health issues worldwide. By ensuring the availability of these medicines, Upjohn contributes significantly to public health efforts globally.

Key Takeaways

• Upjohn has a rich history of pharmaceutical innovation, including breakthroughs in cortisone production and the development of prednisone.
• The company's strength lies in its portfolio of established, iconic brands and its global manufacturing capabilities.
• Upjohn's merger with Mylan to form Viatris has created a new global pharmaceutical powerhouse with expanded capabilities and market reach.
• The company faces challenges related to patent expirations and regulatory changes but is well-positioned to leverage its strengths in established markets and expand in emerging economies.
• Continued innovation and adaptation to changing market dynamics will be crucial for Upjohn's future success as part of Viatris.

FAQs

1. What are some of Upjohn's most well-known pharmaceutical products? Upjohn is known for products such as Xanax, Halcion, Motrin, Lincocin, and Rogaine.

2. How has Upjohn contributed to pharmaceutical research? Upjohn developed a process for large-scale cortisone production in 1952 and contributed to the development of prednisone. The company also developed the Upjohn dihydroxylation, a significant contribution to chemical research.

3. What was the strategic rationale behind the merger of Upjohn and Mylan? The merger aimed to create a company with increased scale, expanded geographic presence, a diversified product portfolio, and enhanced R&D capabilities.

4. How does Upjohn's focus on established medicines impact global health? By ensuring the availability of proven treatments, particularly in emerging markets, Upjohn plays a crucial role in addressing prevalent health issues worldwide and improving access to essential medicines.

5. What are the main challenges facing Upjohn in the current pharmaceutical landscape? Key challenges include patent expirations, generic competition, navigating complex regulatory environments, and adapting to potential healthcare policy changes.

Sources cited: [1] https://en.wikipedia.org/wiki/Upjohn [2] https://www.pfizer.com/news/press-release/press-release-detail/mylan_and_upjohn_a_division_of_pfizer_to_combine_creating_a_new_champion_for_global_health_uniquely_positioned_to_fulfill_the_world_s_need_for_medicine [3] https://abudhabi2019.fip.org/sponsor-pfizer-upjohn/ [6] https://www.pfizer.com/files/investors/financial_reports/annual_reports/2019/our-bold-moves/transform-our-go-to-market-model/combining-upjohn-and-mylan-to-create-a-new-champion-for-global-health/index.html [7] https://investor.viatris.com/static-files/e12db82c-73b8-488b-a081-3e1d746ebd31 [8] https://www.latimes.com/archives/la-xpm-1993-04-12-fi-22033-story.html